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Septic shock is a syndrome in which pro-in-
flammatory and anti-inflammatory processes are
dynamically interconnected and regulated. Cen-
tral to these processes is the monocyte, which pro-
duces large quantities of pro-inflammatory cy-
tokines when stimulated with bacterial products.
During the course of sepsis, compensatory anti-in-
flammatory mechanisms may deactivate mono-
cytes and lead to a state of relative “paralysis.” In-
deed, several studies have shown that monocytes
of septic patients are hyporesponsive to potent in-
fectious stimuli [1–2]. These observations support
the hypothesis that anti-inflammatory response
mechanisms may deactivate the monocytes and
lead to a state of “immunoparalysis.” However, it
is unclear whether monocyte/macrophage hy-
poresponsiveness is the result of active down-reg-
ulation or simply reflects a state of “cellular ex-
haustion.” To investigate whether down-regula-
tion of TNFα production was related to shock or
infection, we compared TNFα production of
monocytes after stimulation with LPS, E. coli and
Staph. aureus, using either whole blood or isolated
peripheral blood mononuclear cells of normal vol-
Objectives: In patients with septic shock, circu-
lating monocytes become refractory to stimulation
with microbial products. Whether this hypore-
sponsive state is induced by infection or is related
to shock is unknown. To address this question, we
measured TNFα production by monocytes or by
whole blood obtained from healthy volunteers
(controls), from patients with septic shock, from
patients with severe infection (bacterial pneumo-
nia) without shock, and from patients with cardio-
genic shock without infection.
Measurements: The numbers of circulating
monocytes, of CD14+ monocytes, and the expres-
sion of monocyte CD14 and the LPS receptor,
were assessed by flow cytometry. Monocytes or
whole blood were stimulated with lipopolysaccha-
ride endotoxin (LPS), heat-killed Escherichia coli or
Staphylococcus aureus, and TNFα production was
measured by bioassay. 
Results: The number of circulating monocytes,
of CD14+ monocytes, and the monocyte CD14
expression were significantly lower in patients with
septic shock than in controls, in patients with bac-
terial pneumonia or in those with cardiogenic
shock (p <0.001). Monocytes or whole blood of pa-
tients with septic shock exhibited a profound defi-
ciency of TNFα production in response to all
stimuli (p <0.05 compared to controls). Whole
blood of patients with cardiogenic shock also ex-
hibited this defect (p <0.05 compared to controls),
although to a lesser extent, despite normal mono-
cyte counts and normal CD14 expression.
Conclusions: Unlike patients with bacterial
pneumonia, patients with septic or cardiogenic
shock display profoundly defective TNFα pro-
duction in response to a broad range of infectious
stimuli. Thus, down-regulation of cytokine pro-
duction appears to occur in patients with systemic,
but not localised, albeit severe, infections and also
in patients with non-infectious circulatory failure.
Whilst depletion of monocytes and reduced
monocyte CD14 expression are likely to be criti-
cal components of the hyporesponsiveness ob-
served in patients with septic shock, other as yet
unidentified factors are at work in this group and
in patients with cardiogenic shock.
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Summary
Introduction
unteers and of patients with septic shock, cardio-
genic shock or bacterial pneumonia. To examine
whether down-regulation of TNFα production
was due to cell exhaustion or to a reduced expres-
sion of receptors for microbial products, we quan-
tified the number of monocytes present in the
blood as well as the expression of CD14, which is
a receptor for lipopolysaccharide (LPS), and also
for the peptidoglycan of Gram-positive organisms
[4]. 
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Methods 
Patients
Three groups of patients observed in the Intensive
Care Unit or in the Emergency Rooms of the Depart-
ments of Internal Medicine and Surgery were analysed. A
control group of normal volunteers was included. The
protocol of the study was approved by the Ethics Com-
mittee of the hospital.
Group 1: Patients with septic shock defined by leukocy-
tosis, fever (>38°) or hypothermia (<35.6°C), tachycardia
(>90 beats per minute), tachypnoea (respiratory rate >20
breaths per minute, or needing mechanical ventilation),
and either hypotension (systolic blood pressure <90 mm
Hg) or two of the following signs of systemic toxicity or
peripheral hypoperfusion: unexplained metabolic acidosis
(base excess = 5 mmol/l); arterial hypoxemia, ratio of the
partial pressure of oxygen to the fraction of inspired oxy-
gen <250 mm Hg; hyperlactacidemia; acute renal failure
with urinary output <0.5 ml/kg/h; elevated prothrombin
or partial thromboplastin time; reduction of platelet
counts to less than half of the baseline value; sudden de-
crease in mental acuity; cardiac index of more than 4.l per
minute per square metre of body surface area with sys-
temic vascular resistance of less than 80 dynes  sec 
cm–5.
Group 2: Patients with cardiogenic shock, defined by
hypotension (blood pressure <90 mm Hg or a decrease of
>30 mm Hg in a hypertensive patient) or needing cata-
cholamines to maintain blood pressure (dopamine or
dobutamine >5 µg/kg/min), and by cardiac index <2
l/min/m2 or systolic index <20 ml/m2 and pulmonary cap-
illary wedge pressure >16 mm Hg.
Group 3: Patients with severe community-acquired
bacterial pneumonia. Community-acquired pneumonia was
diagnosed according to the following criteria: a new in-
filtrate seen on chest X ray in the presence of two or more
symptoms, signs or values such as fever of >38°C, cough,
purulent sputum, leukocytosis of >10 000/mm3. Pneumo-
nia was considered to be microbiologically documented if
isolates from sputum or tracheal aspirate cultures con-
tained a predominant bacterium, more than 25 neu-
trophils and less than 10 epithelial cells per low power field
(100) on microscopy. Patients with nosocomial pneu-
monia were excluded.
Ten patients with septic shock (mean APACHE score:
22, ranging from 17 to 30), 10 patients with bacterial pneu-
monia (mean APACHE score:13, ranging from 4 to 23),
10 patients with cardiogenic shock (mean APACHE
score:10, ranging from 6 to 20), and 10 controls were
analysed. The clinical status of these patients has been pre-
viously described [5]. All patients with septic shock or
pneumonia had positive cultures. Pathogens in patients
with sepsis or pneumonia included P. aeruginosa,  E. coli,
S. pneumoniae, S. pyogenes, Legionella sepsis, and P. mirabilis.
Two patients with sepsis had fungal (Candida) infections.
Patients with cardiogenic shock had no signs of infection. 
Blood sampling
Blood was collected in sterile heparin tubes contain-
ing. Samples were taken on day 1 or 2 in patients with sep-
tic or cardiogenic shock, and on day 1 in patients with bac-
terial pneumonia. Blood from normal volunteers was ob-
tained from the Swiss Red Cross Transfusion Center. 
Stimulation assay
200 µl heparinised whole blood was stimulated with
10 ng/ml of E.coli O111 LPS (Sigma, St. Louis, Missouri),
106 heat-killed E. coli O111 or Staph. aureus, for 4 hours 
at 37°C. TNFα was measured in the supernatant by bioas-
say, using WEHI clone 13 as target cells [6]. The lower
limit of sensitivity of the bioassay is 25 pg/ml of bioactive
TNFα. 
An alternative protocol of stimulation was used in se-
lected patients with septic shock. 106 peripheral blood
mononuclear cells (PBMC), obtained by Ficoll centrifu-
gation were mixed with 10% pooled plasma from normal
volunteers and incubated with 10 ng/ml LPS for 4 hours
at 37°C. TNFα was measured after 4 h incubation. In this
short-term assay, monocytes are the major source of blood
TNFα [6].
Endogenous TNFα measurement
Endogenous TNFα present in serum was measured
by ELISA (Medgenix, Endotell, Basel, Switzerland).
Number of monocytes and CD14 expression
Total white blood cells and total monocyte counts
were assessed in the haematology laboratory (Prof. M
Schapira, CHUV). Peripheral blood mononuclear cells
(PBMC) were obtained by Ficoll centrifugation. Using
side-scatter analysis, the percentage of CD14+ monocytes
was evaluated by reacting PBMC with an anti-CD14 mAb
(Leu M3) labelled with FITC (Coulter clone, Instru-
menten Gesellschaft, Zürich). CD14 expression was esti-
mated by the mean fluorescence value observed on mono-
cytes reacted with anti-CD14 labelled with FITC by FAC
scan (FACS) analysis. 
Statistical methods
Comparisons between groups were evaluated with
the ANOVA ranks test.
Results
Production of TNFα in whole blood 
Compared to controls, whole blood of patients
with septic shock showed a profound reduction of
TNFα release after stimulation with LPS, heat-
killed E. coli or Staph. aureus (table 1). Production
of TNFα was also markedly decreased in whole
blood of patients with cardiogenic shock. In con-
trast, production of TNFα in whole blood of pa-
tients with bacterial pneumonia was similar to that
of normal volunteers. 
Role of monocytes versus plasma in TNFα
down-regulation in septic shock patients
challenged with LPS 
The down-regulation of TNFα production
observed in patients with septic shock could be me-
diated by inhibitory factors present in the plasma
or due to hyporesponsive monocytes. To investi-
gate this, whole blood of 6 patients with septic
shock or their isolated PBMC in the presence of a
pool of plasma obtained from normal volunteers
were stimulated with LPS. TNFα production was
0.16 ± 0.22 ng/ml in whole blood and 0.17 ± 0.33
ng/ml in isolated PBMC, indicating that normal
plasma did not restore TNFα production. Thus,
in this group of patients with septic shock, defec-
tive TNFα production is not mediated by in-
hibitory factors present in plasma, but is probably
due to quantitative and qualitative cellular defects.
Correlation between monocytes, 
CD14 expression and TNFα production
We went on to investigate whether TNFα
down-regulation was due to a reduction either in
the total numbers of circulating monocytes or of
CD14+ monocytes, or to a decreased expression of
CD14 on monocytes. Indeed, LPS and other bac-
terial products induce cytokine release in blood via
the monocyte receptor CD14 [7]. The total num-
ber of monocytes in the PBMC preparation, the
percentage of monocytes expressing CD14 and the
expression of CD14 evaluated by FACS analysis
are shown in table 2. All but two patients with sep-
tic shock had decreased monocyte counts, a de-
creased number of CD14+ monocytes and a re-
duced expression of CD14 associated with low
TNFα production. In contrast, patients with sep-
tic shock, patients with bacterial pneumonia (with
the exception of 1 of 10) and those with cardio-
genic shock had normal numbers of monocytes
and CD14 expression similar to controls. Yet, de-
spite normal monocyte counts and normal CD14
expression, TNFα production was markedly re-
duced in patients with cardiogenic shock. 
Correlation between endogenous TNFα
and TNFα produced by LPS stimulation 
in whole blood of septic shock patients
Initial serum TNFα concentrations in patients
with septic shock were measured by ELISA, which
measures both unbound TNFα and TNFα bound
to soluble TNF receptors. Circulating TNFα lev-
els ranged from 80 pg/ml to 520 pg/ml (Figure 1).
However, this TNFα was not biologically active as
it was undetectable by bioassay, which only detects
unbound TNFα  (data not shown), indicating that
in these patients TNFα was associated with circu-
lating TNF receptors. TNFα produced by stimu-
lating whole blood of these patients with LPS was
active by bioassay, and inversely correlated with
serum TNFα initially present in the samples 
(fig. 1).
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TNFα (ng/ml) produced after stimulation with
LPS E. coli Staph. aureus
P P P
Controls 1.82 ± 1.69 6.01 ± 3.72 1.56 ± 1.94
Septic shock 0.18 ± 0.44 0.003 0.36 ± 0.65 0.001 0.12 ± 0.26 0.003
Cardiogenic shock 0.23 ± 0.23 0.004 1.12 ± 0.78 0.002 0.31 ± 0.38 0.003
Pneumonia 1.20 ± 1.45 0.27 4.87 ± 4.66 0.87 1.32 ± 2.43 0.25
Whole blood was stimulated with 10 ng/ml LPS, 106 heat-killed E. coli or Staph. aureus, and TNFα measured in plasma after 4 h
of stimulation. Data are expressed as mean ± SD of 10 samples for each group of patients. P values were calculated with the
ANOVA rank test when comparing patients with controls. Values measured in the septic shock group versus those of the cardio-
genic shock group, as well as values measured in the pneumonia group versus those of controls were not statistically different.
Table 1
ΤΝFα production by
whole blood of
normal volunteers
(controls), patients
with septic shock,
with cardiogenic
shock or with severe
bacterial pneumonia
after stimulation 
with LPS, E. coli and
Staph. aureus.
Median (range) Mean ± SD
Controls
TNFα (ng/ml) 1.35 (0.26–5.58) 1.82 ± 1.69
Total Mo 10-3 17.5 (6–36) 20.9   ± 10.5
% CD14+ Mo 84 (52–92) 80.6   ± 12.1
CD14 (FU) 74 (50–90) 72.8   ± 16.4
Septic shock
TNFα (ng/ml) 0 (0–1.4) 0.18 ± 0.44*
Total Mo 10-3 <1 (<1–17) 6.3   ± 7.5*
% CD14+ Mo 35 (<1–95) 39.1 ± 38.6*
CD14 (FU) 15 (<1–70) 22.8   ± 24.4*
Cardiogenic shock
TNFα (ng/ml) 0.13 (0.03–0.8) 0.23 ± 0.23*
Total Mo 10-3 24 (11–44) 27.3   ± 12.8
% CD14+ Mo 85 (52–98) 85.4   ± 14.8
CD14 (FU) 72 (55–90) 71.3 ± 10.5
Bacterial pneumonia
TNFα (ng/ml) 0.66 (0–4.4) 1.20 ± 1.45
Total Mo 10-3 17 (<1–42) 19.8   ± 15.7
% CD14+ Mo 87 (<1–97) 70.5   ± 28.7
CD14 (FU) 55 (<1–92) 57.4   ± 25.9
Whole blood was stimulated with 10 ng/ml of LPS and TNFα
content of supernatants was measured by bioassay. The total
number of monocytes/ml of blood (Total Mo  10-3) was enu-
merated. Peripheral blood mononuclear cells (PBMC) were
obtained by Ficoll centrifugation. The percentage of CD14+
monocytes was evaluated by reacting PBMC with a FITC-
anti-CD14 mAb, and expression of CD14 was measured by
FACS analysis (FU, fluorescence units). Results are expressed
as median (range) and mean ± SD of the 10 individual sam-
ples/group. * p <0.001 when comparing controls with the
other groups (ANOVA on ranks).
Table 2
ΤΝFα production and
number of circulating
monocytes, CD14+
monocytes, and
CD14 expression in
normal healthy vol-
unteers (controls)
and in patients with
septic shock, cardio-
genic shock or severe
bacterial pneumonia. 
CD14 expression on monocytes and TNFα production in patients with septic shock, cardiogenic shock or bacterial pneumonia 38
Figure 1
Correlation between serum concentrations of TNFα and
TNFα produced ex vivo by LPS-stimulated blood of pa-
tients with septic shock. Serum TNFα was measured by
ELISA. TNFα produced ex vivo by whole blood stimulated
with LPS was measured by bioassay.
Discussion
A profound down-regulation of monocyte ac-
tivation by bacterial products as measured by
TNFα production was observed in patients with
septic shock or with cardiogenic shock, but not in
patients with bacterial pneumonia. Patients who
did not produce ex vivo TNFα in response to LPS
had the highest serum TNFα levels, suggesting
that when monocytes have been activated in vivo,
they were less likely to respond to a further stim-
ulation in vitro.
It is well documented that monocytes presen-
sitised with LPS have a markedly reduced capacity
to produce pro-inflammatory cytokines (especially
TNFα) in response to a second LPS stimulation
[8]. This phenomenon also occurs in vivo and has
been called tolerance, adaptation, or hyporespon-
siveness. Several mechanisms have been proposed
to explain how monocytes from healthy donors be-
come tolerant to LPS. Among these are the down-
regulation of LPS receptors, the induction of in-
hibitory molecules or the production of anti-in-
flammatory mediators, such as anti-inflammatory
cytokines or glucocorticoid hormones [8]. Al-
though similarities exist between LPS-tolerant
monocytes and monocytes isolated from critically-
ill or septic patients, there are important differ-
ences as well, as demonstrated in the present study.
In septic shock patients, blood samples with the
lowest numbers of monocytes and a reduced ex-
pression of CD14 produced less TNFα in re-
sponse to LPS stimulation than blood samples
containing normal monocyte levels. Reduced
TNFα production in septic shock patients was
clearly associated with a reduced number of mono-
cytes and a decreased expression of CD14. The
mechanisms of, and reasons for a profound down-
regulation of CD14 receptors remain unknown. At
low concentrations of LPS, CD14 is the receptor
for LPS on cells of the myelomonocytic lineage
[7], whereas CD18 might serve as an alternative re-
ceptor at high concentrations of LPS [9]. Expres-
sion of CD14 and CD18 on LPS-tolerant normal
monocytes was found to be unchanged or even up-
regulated [10–13], suggesting that down-regula-
tion of receptors does not account for LPS toler-
ance in normal monocytes. In sharp contrast to
what was seen in the tolerant state, monocyte
CD14 expression has repeatedly been reported to
be profoundly reduced in the severely injured or in
septic patients [14–18]. The mechanisms respon-
sible for decreased CD14 expression are far from
understood. In vitro, bacterial products have been
shown to increase CD14 expression and survival 
of monocytes [19], while anti-inflammatory cy-
tokines usually down-regulate CD14 expression
[20]. In fact, it has been documented that increased
levels of circulating soluble CD14 are found in
patients with septic shock [21]. Interestingly,
down-regulation of CD14 expression has recently
been shown to be sufficient to trigger monocyte
apoptosis [20]. If similar mechanisms occur in sep-
tic patients, one could postulate that the anti-in-
flammatory response induces down-regulation of
CD14 and therefore monocyte apoptosis.
Brandtzaeg and coworkers have investigated
whether anti-inflammatory cytokines might be re-
sponsible for the profound down-regulation ob-
served in the blood of septic patients. By mixing
normal monocytes and plasma from septic patients
(with or without shock), they observed that IL-10
present in the plasma of shock patients was re-
sponsible for the suppression of the response of
normal monocytes to LPS [3]. While this situation
may occur in patients with meningoccaemic septic
shock with elevated IL-10 levels (up to 40 ng/ml),
it is unlikely to contribute importantly in most
cases of septic shock, in which serum levels do not
exceed 1 ng/ml (a concentration which does not in-
hibit synthesis of pro-inflammatory molecules). In
fact, the present observations rather suggest that
the predominant cause of down-regulation is the
monocyte itself, since monocytes of patients with
septic shock did not respond to LPS stimulation
even in the presence of plasma from healthy indi-
viduals. Yet, this does not rule out a contribution
of anti-inflammatory mechanisms in the process of
dysregulation.
Independently of CD14 expression, of toler-
ance states of monocytes or down-regulation due
to anti-inflammatory mechanisms, a striking ob-
servation of the present study was the very low
numbers of circulating monocytes found in septic
shock patients, an observation that may per se ac-
count for the low levels of TNFα produced upon
stimulation with microbial products. Since shock
is known to trigger macrophage apoptosis [23],
monocytes of septic patients may consist of a mix-
ture of normal and dying monocytes. In contrast
to patients with septic shock, patients with bacte-
rial pneumonia or with cardiogenic shock had nor-
mal numbers of monocytes and normal expression
of CD14. However, some of these patients failed
to produce TNFα in response to LPS stimulation,
which cannot be explained by CD14 down-regu-
lation or the presence of apoptotic monocytes.
Although LPS, peptidoglycan and lipoteichoic
acid, whole Gram-positive or Gram-negative bac-
teria may share a CD14-dependent signalling
pathway [4], mechanisms other than CD14 down-
regulation may also account for the profound dys-
regulation of monocyte function. Such mecha-
nisms may explain why patients with cardiogenic
shock exhibited normal monocyte counts and
CD14 expression, and yet were hyporesponsive to
LPS stimulation. The causes for down-regulation
in cardiogenic shock patients are not known. The
elevated levels of endogenous catecholamines in
such patients together with the fact that these pa-
tients were treated with such amines could account
for this down-regulation. Indeed, catecholamines
are known to depress monocyte activation [24].
Similar mechanisms may also occur in patients
with septic shock, since patients with septic shock
usually also require catecholamines. To answer this
question, a detailed analysis of the cytokine-in-
ducing potential of whole blood of septic shock pa-
tients would require blood sampling before the ad-
ministration of catecholamines. Yet, the more sig-
nificant defect in cytokine production observed in
samples of patients with septic shock compared to
those with cardiogenic shock may be related to ad-
ditional mechanisms involving monocyte func-
tion.
Conclusions
In summary, the present data indicate that
numbers of monocytes in patients with septic
shock are depleted and that sepsis is associated with
a profound dysregulation of monocyte function
more complex than explained by LPS tolerance
alone. Such down-regulation was a hallmark of
septic shock, and was not restricted to patients with
Gram-negative infections. Down-regulation of
monocytes was also found to occur in patients with
cardiogenic shock, but not in patients with bacte-
rial pneumonia. This suggests that the presence of
an infectious focus alone does not necessarily lead
to “immunoparalysis.” The causes of “immuno-
paralysis” in sepsis remain to be determined.
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